HK1052338A1 - Compounds for modulating the rage receptor - Google Patents
Compounds for modulating the rage receptorInfo
- Publication number
- HK1052338A1 HK1052338A1 HK03103492A HK03103492A HK1052338A1 HK 1052338 A1 HK1052338 A1 HK 1052338A1 HK 03103492 A HK03103492 A HK 03103492A HK 03103492 A HK03103492 A HK 03103492A HK 1052338 A1 HK1052338 A1 HK 1052338A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compounds
- rage
- diseases
- development
- end products
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/40—Radicals substituted by oxygen atoms
- C07D307/42—Singly bound oxygen atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20734300P | 2000-05-30 | 2000-05-30 | |
US09/799,317 US6613801B2 (en) | 2000-05-30 | 2001-03-05 | Method for the synthesis of compounds of formula I and their uses thereof |
PCT/US2001/017251 WO2001092210A1 (en) | 2000-05-30 | 2001-05-25 | Compounds for modulating the rage receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1052338A1 true HK1052338A1 (en) | 2003-09-11 |
Family
ID=26902168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK03103492A HK1052338A1 (en) | 2000-05-30 | 2003-05-16 | Compounds for modulating the rage receptor |
Country Status (12)
Country | Link |
---|---|
US (4) | US6613801B2 (de) |
EP (2) | EP1642888B1 (de) |
JP (1) | JP4451058B2 (de) |
AT (2) | ATE531688T1 (de) |
AU (2) | AU780368B2 (de) |
CA (2) | CA2379695C (de) |
DE (1) | DE60112079T2 (de) |
DK (1) | DK1284959T3 (de) |
ES (2) | ES2243506T3 (de) |
HK (1) | HK1052338A1 (de) |
MX (1) | MXPA02001099A (de) |
WO (1) | WO2001092210A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US7087632B2 (en) * | 2001-03-05 | 2006-08-08 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
NZ523483A (en) * | 2000-07-06 | 2004-08-27 | Array Biopharma Inc | Tyrosine derivatives as phosphatase inhibitors |
EP1377295A4 (de) * | 2001-03-05 | 2007-05-09 | Transtech Pharma Inc | Carbonsäureamid-derivative als therapeutische mittel |
EP1453531B1 (de) * | 2001-12-19 | 2008-05-14 | Alcedo Biotech GmbH | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren |
WO2003075921A2 (en) * | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
WO2003103660A1 (en) * | 2002-06-11 | 2003-12-18 | Wyeth | Substituted phenylsulfonamide inhibitors of beta amyloid production |
GB0220216D0 (en) * | 2002-08-30 | 2002-10-09 | Novo Pharmaceuticals De Ltd | Compounds and their use |
WO2004079368A2 (en) | 2003-03-08 | 2004-09-16 | Auvation Ltd | Markers for colorectal cancer |
CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
US20070154954A1 (en) * | 2004-03-18 | 2007-07-05 | Transtech Pharma, Inc. | Fluorescence polarization assay |
EP1771565B1 (de) * | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivate |
CA2573856A1 (en) * | 2004-08-03 | 2006-02-16 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
ES2473587T3 (es) | 2004-08-03 | 2014-07-07 | Transtech Pharma, Inc. | Proteínas de fusión de RAGE y métodos de uso |
NZ552842A (en) * | 2004-08-03 | 2010-05-28 | Univ Columbia | Rage fusion proteins and methods of use |
AU2005289594B2 (en) | 2004-09-27 | 2012-02-02 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
US20070087406A1 (en) * | 2005-05-04 | 2007-04-19 | Pei Jin | Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same |
WO2007044309A2 (en) * | 2005-10-05 | 2007-04-19 | Vasix Corporation | Device and method for inhibiting age complex formation |
US20080295194A1 (en) * | 2007-04-02 | 2008-11-27 | Miami University | Transgenic plants with enhanced characteristics |
WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
KR101595634B1 (ko) | 2007-06-14 | 2016-02-18 | 갈락티카 파마슈티칼스, 인크. | Rage 융합 단백질 |
RU2011142230A (ru) | 2009-04-20 | 2013-05-27 | Пфайзер Инк. | Контроль гликозилирования белка и композиции и способы, касающиеся этого |
WO2011041198A1 (en) | 2009-09-30 | 2011-04-07 | Transtech Pharma, Inc. | Substituted imidazole derivatives for treatment of alzheimers disease |
EP2536283B8 (de) | 2010-02-18 | 2015-11-04 | vTv Therapeutics LLC | Phenylheteroarylderivate und verwendungsverfahren dafür |
JP2013529193A (ja) * | 2010-04-26 | 2013-07-18 | ネステク ソシエテ アノニム | 非経口栄養から経腸栄養へ離脱させるための栄養組成物及び方法 |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
EP3822291A1 (de) | 2015-06-10 | 2021-05-19 | The Broad Institute Inc. | Antikörper, verbindungen und tests zur identifizierung und behandlung von kachexie oder präkachexie |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
EP3864008A1 (de) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metaboliten von [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amin |
CN111825576B (zh) * | 2020-07-21 | 2023-10-27 | 安徽东凯生物科技股份有限公司 | 一种氨基酸制备方法 |
CN117843513B (zh) * | 2024-03-07 | 2024-05-28 | 深圳创元生物医药科技有限公司 | 一种(S)-3-Carboxytyrosine的制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
IL55573A0 (en) | 1977-10-03 | 1978-12-17 | Erba Carlo Spa | Substituted n-(ss-alkoxy-ethyl)-n-(4-phenoxybenzyl)-dichloroacetamides and process for their preparation |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
US5202424A (en) | 1984-03-19 | 1993-04-13 | The Rockefeller University | Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof |
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
US4873313A (en) | 1985-01-18 | 1989-10-10 | Beckman Research Institute Of City Of Hope | Specific hybridoma cell line and monocolonal antibodies produced from such specific hybridoma cell line and method of using such monoclonal antibodies to detect carcinoembryonic antigens |
US4963539A (en) * | 1987-09-10 | 1990-10-16 | E. R. Squibb & Sons, Inc. | Phosphonate and phosphonamide endopeptidase inhibitors |
US5153226A (en) * | 1989-08-31 | 1992-10-06 | Warner-Lambert Company | Acat inhibitors for treating hypocholesterolemia |
CN1078886C (zh) | 1993-10-01 | 2002-02-06 | 默里尔药物公司 | 抑制β-淀粉样蛋白产生的抑制剂 |
GB9409150D0 (en) * | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
US5597845A (en) | 1994-06-20 | 1997-01-28 | Merrell Pharmaceuticals Inc. | Substituted alkyldiamine derivatives |
US5939526A (en) | 1995-03-21 | 1999-08-17 | Ludwig Institute For Cancer Research | Isolated RAGE-1 derived peptides which complex with HLA-B7 molecules and uses thereof |
ES2224164T3 (es) | 1995-04-13 | 2005-03-01 | Aventis Pharmaceuticals Inc. | Nuevos derivados de piperazina sustituida que tienen actividad como antagonistas de los receptores de taququinina. |
US6228858B1 (en) | 1995-09-12 | 2001-05-08 | University Of Kansas Medical Center | Advanced glycation end-product intermediaries and post-amadori inhibition |
US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5688653A (en) | 1996-06-27 | 1997-11-18 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
ATE304528T1 (de) | 1996-07-22 | 2005-09-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US6790443B2 (en) | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US6004958A (en) | 1997-02-05 | 1999-12-21 | Fox Chase Cancer Center | Compounds and methods for therapeutic intervention in preventing diabetic complications and procedures for assessing a diabetic's risk of developing complications and determining the efficacy of therapeutic intervention |
US6100098A (en) | 1997-02-18 | 2000-08-08 | Mcgill University | Anti-AGE IgG and uses thereof for the diagnosis of severe disease |
US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
DK1066247T3 (da) | 1998-03-31 | 2007-04-02 | Vertex Pharma | Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease |
US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
US6753150B2 (en) | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
EP1121454B1 (de) | 1998-10-06 | 2007-11-14 | The Trustees of Columbia University in the City of New York | Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen |
US6613801B2 (en) * | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
-
2001
- 2001-03-05 US US09/799,317 patent/US6613801B2/en not_active Expired - Fee Related
- 2001-05-25 EP EP05076535A patent/EP1642888B1/de not_active Expired - Lifetime
- 2001-05-25 CA CA002379695A patent/CA2379695C/en not_active Expired - Fee Related
- 2001-05-25 CA CA002599562A patent/CA2599562A1/en not_active Abandoned
- 2001-05-25 AT AT05076535T patent/ATE531688T1/de active
- 2001-05-25 ES ES01939581T patent/ES2243506T3/es not_active Expired - Lifetime
- 2001-05-25 AT AT01939581T patent/ATE299860T1/de active
- 2001-05-25 WO PCT/US2001/017251 patent/WO2001092210A1/en active IP Right Grant
- 2001-05-25 JP JP2002500825A patent/JP4451058B2/ja not_active Expired - Fee Related
- 2001-05-25 MX MXPA02001099A patent/MXPA02001099A/es active IP Right Grant
- 2001-05-25 DK DK01939581T patent/DK1284959T3/da active
- 2001-05-25 EP EP01939581A patent/EP1284959B1/de not_active Expired - Lifetime
- 2001-05-25 AU AU65083/01A patent/AU780368B2/en not_active Ceased
- 2001-05-25 DE DE60112079T patent/DE60112079T2/de not_active Expired - Lifetime
- 2001-05-25 ES ES05076535T patent/ES2373557T3/es not_active Expired - Lifetime
-
2003
- 2003-05-16 HK HK03103492A patent/HK1052338A1/xx not_active IP Right Cessation
- 2003-07-01 US US10/611,741 patent/US7067554B2/en not_active Expired - Fee Related
-
2005
- 2005-02-02 AU AU2005200425A patent/AU2005200425B2/en not_active Ceased
-
2006
- 2006-01-12 US US11/331,256 patent/US20060189578A1/en not_active Abandoned
- 2006-02-27 US US11/362,993 patent/US20060148760A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1284959T3 (da) | 2005-11-21 |
US7067554B2 (en) | 2006-06-27 |
EP1284959B1 (de) | 2005-07-20 |
US20060148760A1 (en) | 2006-07-06 |
AU780368B2 (en) | 2005-03-17 |
US6613801B2 (en) | 2003-09-02 |
AU2005200425A1 (en) | 2005-02-24 |
US20040097407A1 (en) | 2004-05-20 |
EP1642888B1 (de) | 2011-11-02 |
DE60112079D1 (de) | 2005-08-25 |
ATE299860T1 (de) | 2005-08-15 |
ES2243506T3 (es) | 2005-12-01 |
ATE531688T1 (de) | 2011-11-15 |
JP4451058B2 (ja) | 2010-04-14 |
CA2599562A1 (en) | 2001-12-06 |
ES2373557T3 (es) | 2012-02-06 |
AU2005200425B2 (en) | 2009-01-15 |
WO2001092210A1 (en) | 2001-12-06 |
CA2379695A1 (en) | 2001-12-06 |
US20060189578A1 (en) | 2006-08-24 |
DE60112079T2 (de) | 2006-06-01 |
EP1284959A1 (de) | 2003-02-26 |
MXPA02001099A (es) | 2004-04-05 |
US20020006957A1 (en) | 2002-01-17 |
EP1642888A1 (de) | 2006-04-05 |
CA2379695C (en) | 2007-11-27 |
AU6508301A (en) | 2001-12-11 |
JP2004519416A (ja) | 2004-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1052338A1 (en) | Compounds for modulating the rage receptor | |
WO2002070473A3 (en) | Carboxamide derivatives as therapeutic agents | |
WO2003075921A3 (en) | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage | |
WO2005052002A3 (en) | Single-domain antibodies and uses thereof | |
WO2001009118A3 (en) | Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
BRPI0518322A2 (pt) | composiÇço, kit, e, mÉtodos para tratar uma condiÇço, para reverter um efeito no sistema nervoso central de um agente, para tratar um animal de dor, e para controlar dor crânica | |
WO2003099771A3 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
WO2005007652A3 (en) | Substituted quinolin-4-ylamine analogues | |
EP1262177A3 (de) | Medizinische Verwendung thyromimetischer Verbindungen gegen Haarausfall und Zusammensetzungen | |
WO2005007648A3 (en) | Biaryl piperazinyl-pyridine analogues | |
BRPI0313792B8 (pt) | utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento | |
WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
WO2004110151A8 (en) | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments | |
WO2003017939A3 (en) | Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment | |
WO2002098362A3 (en) | Use of rank antagonists to treat cancer | |
WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
PT1237562E (pt) | Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas | |
WO2004056768A3 (en) | Use of substituted 2,5-diamidoindoles for the treatment of urological diseases | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
WO2003080800A3 (en) | Prevention and treatment of disease using angiogenesis-and/or tumor antigens | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
WO2000043028A3 (en) | Method of treating chronic cardiac disease | |
BR0214301A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratar doenças ou condições, para potencializar um efeito terapêutico de um agente do snc, para melhorar a memória recente de um paciente, para determinar a presença ou ausência de um receptor de gabaa em uma amostra, e para alterar a atividade de transdução de sinal de receptor de gabaa, preparação farmacêutica acondicionada, e, uso de um composto ou sal | |
WO2005000406A3 (en) | Treatment of amyloid- and epileptogenesis-associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20140525 |